Atherosclerosis, a chronic inflammatory disorder of the … that inhibition of a specific proinflammatory
cytokine (IL-1β) yielded … on targeting inflammation for atherosclerosis, focusing on …

… When targeting inflammatory cytokines, some anti-atherosclerotic drugs are able to slow the
… atherosclerosis caused by lipid-lowering and reduces circulating inflammatory cytokines in …

Atherosclerosis (AS) features include progressive hardening and reduced elasticity of
arteries. AS is the leading cause of morbidity and mortality. An increasing amount of evidence …

… Cytokines have previously been recognized as promising therapeutic targets for atherosclerosis,
and a … cytokines attenuates disease progression [3, 4], supporting the critical role of …

… In recent years, TLRs have gained special attention as promising therapeutic targets for AS.
As the quest for increasingly effective medications is crucial, we discuss the involvement of …

… that MSTFs represent promising therapeutic targets for the prevention of atherosclerosis. Due
… and IL-18, both proinflammatory cytokines involved in the atherosclerotic process, are also …

… cytokines has been added to the repertoire of atherosclerotic pathophysiology over the last
decade. For example, IL-8 is generally considered a chemotactic cytokine … atherosclerosis, …

… , and interferon γ (IFN-γ) displayed additive effects on VCAM-1 expression at low concentrations,
VCAM-1 protein levels are lower at higher concentrations of the combined cytokines […

… This review provides an overview of cytokines in atherosclerosis, the potential benefits
and risks associated with targeted anticytokine therapies, and a look to the future of clinical …

… focuses on recent and novel nucleic acid–based therapies, which have advanced into clinical
development during the past 3 years and describe also new promising therapeutic targets …